GlassScriptPhysician profile
Richard A Hefner
NPI 1639102585
$2,904.59
in general payments reported to CMS, 2019-2025
36 companies · $624 in 2025
The $624 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,021 · 2020: $228 · 2021: $199 · 2022: $169 · 2023: $211 · 2024: $453 · 2025: $624.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,287.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,287.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $440.19 | 2019-2025 | |
| Pfizer INC. | $322.41 | 2019-2025 | |
| Amgen INC. | $304.33 | 2019-2025 | Otezla, Repatha, Prolia |
| Astrazeneca Pharmaceuticals LP | $240.92 | 2019-2025 | Farxiga |
| Novo Nordisk INC | $221.81 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Tris Pharma INC | $141.35 | 2022-2024 | Dyanavel Xr |
| Lilly USA, LLC | $126.08 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $120.59 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.93 | 2019-2024 | Jardiance |
| Glaxosmithkline, LLC. | $83.69 | 2019-2024 | Arexvy, Trelegy Ellipta |
| Astellas Pharma US INC | $72.82 | 2019-2024 | Veozah |
| Medtronic, INC. | $66.86 | 2025 | Inpen Smart Insulin Delivery System, Minimed 780g |
| Ironshore Pharmaceuticals INC. | $57.67 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $57.16 | 2019-2025 | Rexulti |
| Exact Sciences Corporation | $49.17 | 2023-2025 | Cologuard Collection Kit |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $45.63 | 2021-2024 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $42.70 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $40.69 | 2024 | Voquezna |
| Novartis Pharmaceuticals Corporation | $39.88 | 2019-2020 | |
| Dynavax Technologies Corporation | $36.00 | 2025 | Heplisav-B |
| Radius Health, INC. | $32.90 | 2019-2024 | Tymlos |
| Merck Sharp & Dohme LLC | $31.89 | 2019-2024 | Capvaxive, Vaxelis, Gardasil |
| Zyla Life Sciences, INC. | $24.72 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $20.51 | 2025 | |
| Antares Pharma, INC. | $20.03 | 2019 | |
| Idorsia Pharmaceuticals US INC | $18.73 | 2024 | Quviviq |
| Eisai INC. | $17.60 | 2021 | |
| Amarin Pharma, INC. | $17.12 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.73 | 2022 | |
| Acella Pharmaceuticals, LLC | $15.37 | 2025 | NP Thyroid 60 |
| Allergan, INC. | $14.23 | 2020 | |
| Tolmar, INC. | $13.91 | 2025 | Jatenzo |
| Jazz Pharmaceuticals INC. | $12.90 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $11.73 | 2021 | |
| Shire North American Group INC | $11.35 | 2019 | |
| Genentech USA, INC. | $10.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Hefner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.